Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue S, 2015, Pages S167-S169

  Choi, Michael Y ^a   Widhopf, George F ^a   Wu, Christina C N ^a   Cui, Bing ^a   Lao, Fitzgerald ^a   Sadarangani, Anil ^a,b   Cavagnaro, Joy ^c   Prussak, Charles ^a   Carson, Dennis A ^a   Jamieson, Catriona ^a,b   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Access BIO   (United States)

Author keywords

AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; ONCOEMBRYONIC ANTIGEN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; UC 961; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; NONHUMAN; APOPTOSIS; HUMAN; IMMUNOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS;

EID: 84939622740     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.010     Document Type: Review

References (24)

1. J. Green, R. Nusse, and R. van Amerongen The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction Cold Spring Harb Perspect Biol 6 2014 pii:a00917
2. P. Masiakowski, and R.D. Carroll A novel family of cell surface receptors with tyrosine kinase-like domain J Biol Chem 267 1992 26181 26190
3. A. Yoda, I. Oishi, and Y. Minami Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans J Recept Signal Transduct Res 23 2003 1 15
4. H.E. Broome, L.Z. Rassenti, H.Y. Wang, L.M. Meyer, and T.J. Kipps ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia Leuk Res 35 2011 1390 1394
5. U. Klein, Y. Tu, G.A. Stolovitzky, and et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells J Exp Med 194 2001 1625 1638
6. A. Rosenwald, A.A. Alizadeh, G. Widhopf, and et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia J Exp Med 194 2001 1639 1647
7. T. Fukuda, L. Chen, T. Endo, and et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a Proc Natl Acad Sci U S A 105 2008 3047 3052
8. G.F. Widhopf II, B. Cui, E.M. Ghia, and et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice Proc Natl Acad Sci U S A 111 2014 793 798
9. S. Zhang, L. Chen, B. Cui, and et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth PLoS One 7 2012 e31127
10. A. Gentile, L. Lazzari, S. Benvenuti, L. Trusolino, and P.M. Comoglio Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis Cancer Res 71 2011 3132 3141
11. A. Gentile, L. Lazzari, S. Benvenuti, L. Trusolino, and P.M. Comoglio The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells Int J Cancer 135 2014 2305 2316
12. J. Yang, S. Baskar, K.Y. Kwong, M.G. Kennedy, A. Wiestner, and C. Rader Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies PLoS One 6 2011 e21018
13. S. Baskar, A. Wiestner, W.H. Wilson, I. Pastan, and C. Rader Targeting malignant B cells with an immunotoxin against ROR1 MAbs 4 2012 349 361
14. C. Berger, D. Sommermeyer, M. Hudecek, and et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells Cancer Immunol Res 3 2015 206 216
15. M. Hudecek, T.M. Schmitt, S. Baskar, and et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor Blood 116 2010 4532 4541
16. R. Mani, Y. Mao, F.W. Frissora, and et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia Leukemia 29 2015 346 355
17. A.H. Daneshmanesh, M. Hojjat-Farsangi, A.S. Khan, and et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells Leukemia 26 2012 1348 1355
18. S. Zhang, L. Chen, J. Wang-Rodriguez, and et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers Am J Pathol 181 2012 1903 1910
19. V. Goede, K. Fischer, R. Busch, and et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N Engl J Med 370 2014 1101 1110
20. M. Hallek, K. Fischer, G. Fingerle-Rowson, and et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
21. T. Robak Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art Expert Rev Hematol 7 2014 841 857
22. B. Cui, S. Zhang, L. Chen, and et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis Cancer Res 73 2013 3649 3660
23. H. Zhang, J. Qiu, C. Ye, and et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer Sci Rep 4 2014 5811
24. S. Zhang, B. Cui, H. Lai, and et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy Proc Natl Acad Sci U S A 111 2014 17266 17271